Post written by Lawrence Hookey, MD, from the Hotel Dieu Hospital, Kingston, Ontario, Canada.

This study is the largest to prospectively evaluate the hemostatic powder TC-325 in lower GI bleeding. We included 50 patients with bleeding from different sources, and performed extensive efficacy and safety follow-up.

TC-325 is a newer product (having just received regulatory approval in the United States), and while there is growing evidence of its efficacy and place in upper GI bleeds, its role in lower GI bleeds is still evolving. This study included patients with different sources of bleeding, with an aim to provide safety and efficacy information.

Fifty patients with acute lower gastrointestinal bleeding were included, and all received TC-325 as therapy. The initial hemostasis rate was high (98%), and we didn’t see any therapy-related adverse events. Thus, the therapy is safe and effective. Future research could investigate whether TC-325 has a role in prophylaxis of bleeding from wide-field mucosal resection or whether it is helpful in acute diverticular hemorrhage, given its advantage of spraying it over a wide field.

Read the full article online.

The information presented in Endoscopedia reflects the opinions of the authors and does not represent the position of the American Society for Gastrointestinal Endoscopy (ASGE). ASGE expressly disclaims any warranties or guarantees, expressed or implied, and is not liable for damages of any kind in connection with the material, information, or procedures set forth.